Antineoplastics
1
Reactions 1364 - 13 Aug 2011 S Antineoplastics Acute myeloid leukaemia: case report An adolescent male developed acute myeloid leukaemia (AML) following treatment with antineoplastics for a fibrosarcoma. He later died. The boy, who was admitted at 14 years of age in January 2001, was diagnosed with a high degree fibrosarcoma. Imaging studies revealed diffuse pulmonary infiltrates. He received chemotherapy with ifosfamide 54 g/m 2 , cyclophosphamide 8 g/m 2 , doxorubicin 320 mg/m 2 and cisplatin 480 mg/m 2 [frequencies and routes not stated]. Mesna and granulocyte colony-stimulating factors were also administered. He completed treatment in November 2002. After 34 months of follow-up, he developed a platelet count of 43 × 10 9 /L and a WBC count of 6.3 × 10 9 /L. A bone marrow aspirate contained 50% blast cells FAB-M2. Results of flow cytometry and RT-PCR led to a diagnosis of therapy- related AML-M2. The boy received treatment according to the AML-BFM 98 protocol; however, he later died during therapy. Subsequent cytogenetic analysis on bone marrow cells revealed an abnormal karyotype with a complex variant translocation, including a translocation involving chromosomes 8 and 13. Soares-Ventura EM, et al. Molecular cytogenetics reveals complex karyotype in apparent t(8;13) therapy-related acute myeloid leukemia M2 after fibrosarcoma. Leukemia Research 35: e27-9, No. 5, May 2011 - Brazil 803058713 1 Reactions 13 Aug 2011 No. 1364 0114-9954/10/1364-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1364 - 13 Aug 2011
SAntineoplastics
Acute myeloid leukaemia: case reportAn adolescent male developed acute myeloid leukaemia
(AML) following treatment with antineoplastics for afibrosarcoma. He later died.
The boy, who was admitted at 14 years of age in January2001, was diagnosed with a high degree fibrosarcoma.Imaging studies revealed diffuse pulmonary infiltrates. Hereceived chemotherapy with ifosfamide 54 g/m2,cyclophosphamide 8 g/m2, doxorubicin 320 mg/m2 andcisplatin 480 mg/m2 [frequencies and routes not stated].Mesna and granulocyte colony-stimulating factors werealso administered. He completed treatment in November2002. After 34 months of follow-up, he developed a plateletcount of 43 × 109/L and a WBC count of 6.3 × 109/L. A bonemarrow aspirate contained 50% blast cells FAB-M2. Resultsof flow cytometry and RT-PCR led to a diagnosis of therapy-related AML-M2.
The boy received treatment according to the AML-BFM98 protocol; however, he later died during therapy.Subsequent cytogenetic analysis on bone marrow cellsrevealed an abnormal karyotype with a complex varianttranslocation, including a translocation involvingchromosomes 8 and 13.Soares-Ventura EM, et al. Molecular cytogenetics reveals complex karyotype inapparent t(8;13) therapy-related acute myeloid leukemia M2 after fibrosarcoma.Leukemia Research 35: e27-9, No. 5, May 2011 - Brazil 803058713
1
Reactions 13 Aug 2011 No. 13640114-9954/10/1364-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
